<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39346045</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2167-8359</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PeerJ</Title><ISOAbbreviation>PeerJ</ISOAbbreviation></Journal><ArticleTitle>Fear of COVID-19 and illicit drug use during COVID-19 pandemic in Japan: a case-control study.</ArticleTitle><Pagination><StartPage>e18137</StartPage><MedlinePgn>e18137</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e18137</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7717/peerj.18137</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Some people use illicit drugs to relieve stress. However, these drugs cause serious damage not only to individuals but also to society as a whole. Stress caused by the COVID-19 pandemic is considerable, as the number of illicit drug users continues to increase, despite a decrease in the availability of drugs and opportunities to leave the house during the pandemic. Fear of COVID-19 causes stress; however, its association with illicit drug use is not yet understood. In this study, we examined whether the fear of COVID-19 affects the subsequent use of illicit drugs.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a retrospective longitudinal case-control study using data from an Internet survey performed annually between 2020-2022, with the 2020 survey as the baseline survey and the 2021 and 2022 surveys as follow-up surveys. Those who were illicit drug use-free at the baseline survey but had a history of drug use upon follow-up were defined as the outcome group, whereas those who remained illicit drug use-free at follow-up were defined as the no-outcome group. Logistic regression analysis was conducted between the two groups, using "the fear of COVID-19" as the explanatory variable and adjusting for the effects of confounding factors. The same analysis was conducted by dividing illicit drugs into cannabis and non-cannabis groups, then setting their use as a secondary outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The study included 17,800 subjects, 837 of whom used illicit drugs at follow-up and 16,963 who did not use illicit drugs at follow-up. Logistic regression analysis revealed that higher levels of fear over COVID-19 correlated with higher illicit drug use among the participants. However, our analysis of cannabis-only outcomes showed no significant differences.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We found that fear of COVID-19 was a contributing factor to illicit drug use. Although the exact mechanism through which fear influences illicit drug use remains unknown, previous studies have shown that fear of certain targets increases illicit drug use, and our study adds to this evidence. However, in this study, we were unable to show a statistically significant causal relationship between fear of COVID-19 and the use of cannabis alone. Further research on the relationship between fear and the use of cannabis or other drugs, for varying focuses of fear, may broaden our knowledge of the different reasons individuals have for using different drugs.</AbstractText><CopyrightInformation>©2024 Nitta et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nitta</LastName><ForeName>Katsuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Naito</LastName><ForeName>Haruaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Faculty of Medicine, Tokai University, Isehara, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabuchi</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Control Center, Department of Cancer Epidemiology, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakiuchi</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Faculty of Medicine, Tokai University, Isehara, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PeerJ</MedlineTA><NlmUniqueID>101603425</NlmUniqueID><ISSNLinking>2167-8359</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013287">Illicit Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="Y">Fear</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013287" MajorTopicYN="Y">Illicit Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084783" MajorTopicYN="N">Recreational Drug Use</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fear</Keyword><Keyword MajorTopicYN="N">Illicit drugs</Keyword><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword></KeywordList><CoiStatement>The authors declare there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346045</ArticleId><ArticleId IdType="pmc">PMC11439375</ArticleId><ArticleId IdType="doi">10.7717/peerj.18137</ArticleId><ArticleId IdType="pii">18137</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdelnour A, Devignes J-C, Randery T, Rogers J. COVID-19 crisis: how distributors can emerge stronger than before. 2020.  [11 December 2023]. https://www.mckinsey.com/industries/industrials-and-electronics/our-insights/covid-19-crisis-how-distributors-can-emerge-stronger-than-before https://www.mckinsey.com/industries/industrials-and-electronics/our-insights/covid-19-crisis-how-distributors-can-emerge-stronger-than-before</Citation></Reference><Reference><Citation>Ahorsu DK, Lin C-Y, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID-19 scale: development and initial validation. International Journal of Mental Health and Addiction. 2022;20:1537–1545. doi: 10.1007/s11469-020-00270-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11469-020-00270-8</ArticleId><ArticleId IdType="pmc">PMC7100496</ArticleId><ArticleId IdType="pubmed">32226353</ArticleId></ArticleIdList></Reference><Reference><Citation>Americas Society/Council of the Americas  The coronavirus in Latin America. 2021.  [26 December 2023]. https://www.as-coa.org/articles/coronavirus-latin-america https://www.as-coa.org/articles/coronavirus-latin-america</Citation></Reference><Reference><Citation>Balon R. Illegal or legal, marijuana remains a gateway drug. Focus. 2018;16(2):s–3s.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493246</ArticleId><ArticleId IdType="pubmed">31975938</ArticleId></ArticleIdList></Reference><Reference><Citation>Berhe NM, Van de Velde S, Rabiee-Khan F, Van der Heijde C, Vonk P, Buffel V, Wouters E, Van Hal G. Knowledge deficit and fear of COVID-19 among higher education students during the first wave of the pandemic and implications for public health: a multi-country cross-sectional survey. BMC Public Health. 2022;22:1144. doi: 10.1186/s12889-022-13511-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-13511-3</ArticleId><ArticleId IdType="pmc">PMC9172614</ArticleId><ArticleId IdType="pubmed">35672723</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AS, Alghababsheh M. COVID-19 and distribution centres operations: the impacts and countermeasures. Heliyon. 2023;9:e18000. doi: 10.1016/j.heliyon.2023.e18000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e18000</ArticleId><ArticleId IdType="pmc">PMC10395339</ArticleId><ArticleId IdType="pubmed">37539213</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  CDC Museum COVID-19 Timeline. 2023.  [08 November 2023]. https://www.cdc.gov/museum/timeline/covid19.html https://www.cdc.gov/museum/timeline/covid19.html</Citation></Reference><Reference><Citation>CDC  Products - vital statistics rapid release - provisional drug overdose data. 2024.  [24 July 2024]. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</Citation></Reference><Reference><Citation>Chacon NC, Walia N, Allen A, Sciancalepore A, Tiong J, Quick R, Mada S, Diaz MA, Rodriguez I. Substance use during COVID-19 pandemic: impact on the underserved communities. Discoveries. 2021;9:e141. doi: 10.15190/d.2021.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.15190/d.2021.20</ArticleId><ArticleId IdType="pmc">PMC8896880</ArticleId><ArticleId IdType="pubmed">35261922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines. 2023;11:682. doi: 10.3390/vaccines11030682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030682</ArticleId><ArticleId IdType="pmc">PMC10054865</ArticleId><ArticleId IdType="pubmed">36992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SX, Ng JCK, Hui BPH, Au AKY, Wu WCH, Lam BCP, Mak WWS, Liu JH. Dual impacts of coronavirus anxiety on mental health in 35 societies. Scientific Reports. 2021;11:8925. doi: 10.1038/s41598-021-87771-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-87771-1</ArticleId><ArticleId IdType="pmc">PMC8076265</ArticleId><ArticleId IdType="pubmed">33903603</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway FN, Samora J, Brinkley K, Jeong H, Clinton N, Claborn KR. Impact of COVID-19 among people who use drugs: a qualitative study with harm reduction workers and people who use drugs. Harm Reduction Journal. 2022;19:72. doi: 10.1186/s12954-022-00653-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12954-022-00653-1</ArticleId><ArticleId IdType="pmc">PMC9250267</ArticleId><ArticleId IdType="pubmed">35780109</ArticleId></ArticleIdList></Reference><Reference><Citation>Czeisler MÉ, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, Weaver MD, Robbins R, Facer-Childs ER, Barger LK, Czeisler CA, Howard ME, Rajaratnam SMW. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic - United States, June (2020) 24-30. MMWR. Morbidity and Mortality Weekly Report. 2020;69:1049–1057. doi: 10.15585/mmwr.mm6932a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6932a1</ArticleId><ArticleId IdType="pmc">PMC7440121</ArticleId><ArticleId IdType="pubmed">32790653</ArticleId></ArticleIdList></Reference><Reference><Citation>Deimel D, Firk C, Stöver H, Hees N, Scherbaum N, Fleißner S. Substance use and mental health during the first COVID-19 lockdown in Germany: results of a cross-sectional survey. International Journal of Environmental Research and Public Health. 2022;19:12801. doi: 10.3390/ijerph191912801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912801</ArticleId><ArticleId IdType="pmc">PMC9566226</ArticleId><ArticleId IdType="pubmed">36232097</ArticleId></ArticleIdList></Reference><Reference><Citation>Esterwood E, Saeed SA. Past epidemics, natural disasters, COVID19, and mental health: learning from history as we deal with the present and prepare for the future. The Psychiatric Quarterly. 2020;91:1121–1133. doi: 10.1007/s11126-020-09808-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11126-020-09808-4</ArticleId><ArticleId IdType="pmc">PMC7429118</ArticleId><ArticleId IdType="pubmed">32803472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira Caceres MM, Sosa JP, Lawrence JA, Sestacovschi C, Tidd-Johnson A, Rasool MHU, Gadamidi VK, Ozair S, Pandav K, Cuevas-Lou C, Parrish M, Rodriguez I, Fernandez JP. The impact of misinformation on the COVID-19 pandemic. AIMS Public Health. 2022;9:262–277. doi: 10.3934/publichealth.2022018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/publichealth.2022018</ArticleId><ArticleId IdType="pmc">PMC9114791</ArticleId><ArticleId IdType="pubmed">35634019</ArticleId></ArticleIdList></Reference><Reference><Citation>Finset A, Bosworth H, Butow P, Gulbrandsen P, Hulsman RL, Pieterse AH, Street R, Tschoetschel R, Van Weert J. Effective health communication - a key factor in fighting the COVID-19 pandemic. Patient Education and Counseling. 2020;103:873–876. doi: 10.1016/j.pec.2020.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2020.03.027</ArticleId><ArticleId IdType="pmc">PMC7180027</ArticleId><ArticleId IdType="pubmed">32336348</ArticleId></ArticleIdList></Reference><Reference><Citation>Galarneau LR, Hilburt J, O’Neill ZR, Buxton JA, Scheuermeyer FX, Dong K, Kaczorowski J, Orkin AM, Barbic SP, Bath M, Moe J, Miles I, Tobin D, Grier S, Garrod E, Kestler A. Experiences of people with opioid use disorder during the COVID-19 pandemic: a qualitative study. PLOS ONE. 2021;16:e0255396. doi: 10.1371/journal.pone.0255396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255396</ArticleId><ArticleId IdType="pmc">PMC8320992</ArticleId><ArticleId IdType="pubmed">34324589</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada  Reduce your risk: choose legal cannabis. 2022.  [24 July 2024]. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/personal-use/reduce-risk-choose-legal.html https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/personal-use/reduce-risk-choose-legal.html</Citation></Reference><Reference><Citation>Health Canada  Canadian Tobacco Alcohol and Drugs (CTADS) Survey in 2017. 2018.  [25 July 2024]. https://www.canada.ca/en/health-canada/services/canadian-alcohol-drugs-survey/2017-summary.html https://www.canada.ca/en/health-canada/services/canadian-alcohol-drugs-survey/2017-summary.html</Citation></Reference><Reference><Citation>Holtgraves T. Social desirability and self-reports: testing models of socially desirable responding. Personality &amp; Social Psychology Bulletin. 2004;30:161–172. doi: 10.1177/0146167203259930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0146167203259930</ArticleId><ArticleId IdType="pubmed">15030631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, Walters EE, Zaslavsky AM. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychological Medicine. 2002;32:959–976. doi: 10.1017/S0033291702006074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291702006074</ArticleId><ArticleId IdType="pubmed">12214795</ArticleId></ArticleIdList></Reference><Reference><Citation>Koçak O, Koçak ÖE, Younis MZ. The psychological consequences of COVID-19 Fear and the moderator effects of individuals’ underlying illness and witnessing infected friends and family. International Journal of Environmental Research and Public Health. 2021;18:1836. doi: 10.3390/ijerph18041836.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18041836</ArticleId><ArticleId IdType="pmc">PMC7917729</ArticleId><ArticleId IdType="pubmed">33668655</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review. Quality &amp; Quantity. 2013;47:2025–2047. doi: 10.1007/s11135-011-9640-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11135-011-9640-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacology, Biochemistry, and Behavior. 2005;81:319–330. doi: 10.1016/j.pbb.2005.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2005.02.017</ArticleId><ArticleId IdType="pubmed">15925403</ArticleId></ArticleIdList></Reference><Reference><Citation>Meller FO, Schäfer AA, Quadra MR, Demenech LM, Paludo SDS, Da Silva PA, Neiva-Silva L, Dumith SC. Fear of covid-19 and health-related outcomes: results from two Brazilian population-based studies. Psychiatry Research. 2022;313:114596. doi: 10.1016/j.psychres.2022.114596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2022.114596</ArticleId><ArticleId IdType="pmc">PMC9065651</ArticleId><ArticleId IdType="pubmed">35526424</ArticleId></ArticleIdList></Reference><Reference><Citation>Midorikawa H, Aiba M, Lebowitz A, Taguchi T, Shiratori Y, Ogawa T, Takahashi A, Takahashi S, Nemoto K, Arai T, Tachikawa H. Confirming validity of the fear of COVID-19 scale in Japanese with a nationwide large-scale sample. PLOS ONE. 2021;16:e0246840. doi: 10.1371/journal.pone.0246840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246840</ArticleId><ArticleId IdType="pmc">PMC7875410</ArticleId><ArticleId IdType="pubmed">33566868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Internal Affairs and Communications  2020 census conducted. 2021.  [28 July 2024]. https://www.stat.go.jp/info/kenkyu/kokusei/yusiki32/pdf/08sy0100.pdf https://www.stat.go.jp/info/kenkyu/kokusei/yusiki32/pdf/08sy0100.pdf</Citation></Reference><Reference><Citation>National Institute on Drug Abuse  Cannabis (Marijuana) DrugFacts. 2019. https://nida.nih.gov/publications/drugfacts/cannabis-marijuana.  [17 July 2024]. https://nida.nih.gov/publications/drugfacts/cannabis-marijuana</Citation></Reference><Reference><Citation>National Institute on Drug Abuse  Drug overdose death rates. 2023.  [23 December 2023]. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates</Citation></Reference><Reference><Citation>National Center for Drug Abuse Statistics,  Drug abuse statistics in 2023. 2020.  [25 July 2024]. https://drugabusestatistics.org/ https://drugabusestatistics.org/</Citation></Reference><Reference><Citation>New York University Web Communications  The impact of COVID-19 on drug use and how it contributes to overdose risk. 2022. https://www.nyu.edu/about/news-publications/news/2022/april/covid-19-drug-use.html.  [14 December 2023]. https://www.nyu.edu/about/news-publications/news/2022/april/covid-19-drug-use.html</Citation></Reference><Reference><Citation>Organized Crime Department. National Police Agency in Japan  Organized crime situation in 2022. 2023.  [24 July 2024]. https://www.npa.go.jp/sosikihanzai/R04sotaijousei/R4jousei.pdf https://www.npa.go.jp/sosikihanzai/R04sotaijousei/R4jousei.pdf</Citation></Reference><Reference><Citation>Rakuten Insight, Inc  About Rakuten Insight. 2002.  [12 December 2023]. https://insight.rakuten.co.jp/beginner/ https://insight.rakuten.co.jp/beginner/</Citation></Reference><Reference><Citation>Sakurai K, Nishi A, Kondo K, Yanagida K, Kawakami N. Screening performance of K6/K10 and other screening instruments for mood and anxiety disorders in Japan. Psychiatry and Clinical Neurosciences. 2011;65:434–441. doi: 10.1111/j.1440-1819.2011.02236.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1819.2011.02236.x</ArticleId><ArticleId IdType="pubmed">21851452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen J, Chartier M, Paulus MP, Stein MB. Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Research. 2006;142:11–17. doi: 10.1016/j.psychres.2006.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2006.01.009</ArticleId><ArticleId IdType="pubmed">16712953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Yatsuya H, Saijo Y, Yoshioka E, Tabuchi T. Psychological distress during the coronavirus disease 2019 pandemic and associated factors among undergraduate students in Japan. Disaster Medicine and Public Health Preparedness. 2022;17:e294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9837417</ArticleId><ArticleId IdType="pubmed">36503566</ArticleId></ArticleIdList></Reference><Reference><Citation>Secades-Villa R, Garcia-Rodríguez O, Jin CJ, Wang S, Blanco C. Probability and predictors of the cannabis gateway effect: a national study. The International Journal on Drug Policy. 2015;26:135–142. doi: 10.1016/j.drugpo.2014.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugpo.2014.07.011</ArticleId><ArticleId IdType="pmc">PMC4291295</ArticleId><ArticleId IdType="pubmed">25168081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha R. Chronic stress, drug use, and vulnerability to addiction. Annals of the New York Academy of Sciences. 2008;1141:105–130. doi: 10.1196/annals.1441.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1441.030</ArticleId><ArticleId IdType="pmc">PMC2732004</ArticleId><ArticleId IdType="pubmed">18991954</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JP, Book SW. Anxiety and substance use disorders: a review. The Psychiatric Times. 2008;25:19–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904966</ArticleId><ArticleId IdType="pubmed">20640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Statista  Addicts and consumers of illegal drugs worldwide 2021. https://www.statista.com/statistics/274688/addicts-and-consumers-of-illegal-drugs-worldwide/  [13 June 2024];2024a </Citation></Reference><Reference><Citation>Statista  World - Total population 2012-2022. 2024b.  [13 June 2024]. https://www.statista.com/statistics/805044/total-population-worldwide/ https://www.statista.com/statistics/805044/total-population-worldwide/</Citation></Reference><Reference><Citation>Suerken CK, Reboussin BA, Sutfin EL, Wagoner KG, Spangler J, Wolfson M. Prevalence of marijuana use at college entry and risk factors for initiation during freshman year. Addictive Behaviors. 2014;39:302–307. doi: 10.1016/j.addbeh.2013.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addbeh.2013.10.018</ArticleId><ArticleId IdType="pmc">PMC4098711</ArticleId><ArticleId IdType="pubmed">24455784</ArticleId></ArticleIdList></Reference><Reference><Citation>Taherdoost H. Validity and reliability of the research instrument; how to test the validation of a questionnaire/survey in a research. 2016. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3205040. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3205040</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3205040</ArticleId></ArticleIdList></Reference><Reference><Citation>Theall KP, Sterk CE, Elifson KW. Perceived neighborhood fear and drug use among young adults. American journal of health behavior. 2009;33:353–365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3763914</ArticleId><ArticleId IdType="pubmed">19182981</ArticleId></ArticleIdList></Reference><Reference><Citation>The Department of Drug Dependence Research  National Community Survey on Drug Use. 2024.  [25 July 2024]. https://www.ncnp.go.jp/nimh/yakubutsu/report/pdf/J_NGPS_2023.pdf https://www.ncnp.go.jp/nimh/yakubutsu/report/pdf/J_NGPS_2023.pdf</Citation></Reference><Reference><Citation>The Japan COVID-19 and Society Internet Survey  How to use the data. 2023.  [13 June 2024]. https://jacsis-study.jp/dug/index.html https://jacsis-study.jp/dug/index.html</Citation></Reference><Reference><Citation>The Asia Pacific Journal  The burdens of self-restraint: social measures and the containment of Covid-19 in Japan. 2022. https://apjjf.org/2022/19/Borovoy.html.  [14 December 2023]. https://apjjf.org/2022/19/Borovoy.html</Citation></Reference><Reference><Citation>United Nations Office on Drugs and Crime  UNODC World Drug Report 2023. 2023.  [13 June 2024].  https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html  https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html</Citation></Reference><Reference><Citation>Velias A, Georganas S, Vandoros S. COVID-19: early evening curfews and mobility. Social Science &amp; Medicine. 2022;292:114538. doi: 10.1016/j.socscimed.2021.114538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2021.114538</ArticleId><ArticleId IdType="pmc">PMC8588835</ArticleId><ArticleId IdType="pubmed">34823131</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow ND, Swanson JM, Evins AE, De Lisi LE, Meier MH, Gonzalez R, Bloomfield MAP, Curran HV, Baler R. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73:292–297. doi: 10.1001/jamapsychiatry.2015.3278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2015.3278</ArticleId><ArticleId IdType="pubmed">26842658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D’Souza DC. Marijuana legalization: impact on physicians and public health. Annual Review of Medicine. 2016;67:453–466. doi: 10.1146/annurev-med-050214-013454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-050214-013454</ArticleId><ArticleId IdType="pmc">PMC4900958</ArticleId><ArticleId IdType="pubmed">26515984</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AR. Cannabis as a gateway drug for opioid use disorder. The Journal of Law, Medicine &amp; Ethics: a Journal of the American Society of Law, Medicine &amp; Ethics. 2020;48:268–274. doi: 10.1177/1073110520935338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073110520935338</ArticleId><ArticleId IdType="pmc">PMC7359408</ArticleId><ArticleId IdType="pubmed">32631185</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M-J, Zhao K, Fils-Aime F. Response rates of online surveys in published research: a meta-analysis. Computers in Human Behavior Reports. 2022;7:100206. doi: 10.1016/j.chbr.2022.100206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chbr.2022.100206</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi S, Peltzer K, Pengpid S, Susilowati IH. Prevalence and associated factors of illicit drug use among university students in the association of southeast Asian nations (ASEAN) Substance Abuse Treatment, Prevention, and Policy. 2017;12:9. doi: 10.1186/s13011-017-0096-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13011-017-0096-3</ArticleId><ArticleId IdType="pmc">PMC5382470</ArticleId><ArticleId IdType="pubmed">28381234</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Koyama T, Ishimaru T, Minoura A, Mutoh M, Tabuchi T. Fear of COVID-19 among Japanese workers and exacerbation of chronic pain: a nationwide cross-sectional study. Journal of Occupational and Environmental Medicine/American College of Occupational and Environmental Medicine. 2023;65:e134–e140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9987647</ArticleId><ArticleId IdType="pubmed">36787581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>